Coral Laboratories Ltd Stock Price Today (NSE: CORALAB)
Fundamental Score
Coral Laboratories Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Coral Laboratories Ltd share price today is ₹370.55, down 4.99% on NSE/BSE as of 30 March 2026. Coral Laboratories Ltd (CORALAB) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of ₹175.62 (Cr). The 52-week high for CORALAB share price is ₹784.55 and the 52-week low is ₹360.00. At a P/E ratio of 9.95x, CORALAB is currently trading below its industry average P/E of 31.77x. The company has a Return on Equity (ROE) of 13.06% and a debt-to-equity ratio of 0.00.
Coral Laboratories Ltd Share Price Chart — NSE/BSE Historical Performance
Returns & Performance
ROE
ROCE
OPM (5Y)
Div Yield
Coral Laboratories Ltd Valuation Check
P/E Ratio
Industry P/E
Market Cap
Growth Engine
Profit Growth (Q)
Sales Growth (Q)
Sales Growth (5Y)
EPS Growth (5Y)
Profit Growth (5Y)
Balance Sheet Health
Debt to Equity
Int. Coverage
Free Cash Flow (5Y)
Shareholding
Promoter
FII
DII
Pledged
Institutional Deep-Dive
Bull Run Research Hub
Coral Laboratories Share Price: A Value Investor's Perspective
The pharmaceutical industry, while offering defensive characteristics due to consistent healthcare demand, requires meticulous evaluation, particularly considering potential regulatory headwinds and patent cliffs. This analysis provides a conservative, value-oriented perspective on the "Coral Laboratories share price," currently trading at ₹451.0, with a Price-to-Earnings (PE) ratio of 9.95 and a Return on Capital Employed (ROCE) of 17.44%. This assessment is part of a comprehensive 80-parameter fundamental audit, meticulously verified by Sweta Mishra, focusing on capital preservation.
Coral Laboratories' PE ratio of 9.95 suggests it may be undervalued compared to the broader market, but deeper investigation is warranted. A crucial aspect of value investing is understanding management quality. While
Mankind Pharma Ltd commands a premium valuation partly due to its established brand and perceived management strength, Coral Laboratories requires careful assessment of its leadership team's track record and strategic vision. A comparison of their capital allocation decisions and long-term strategic planning could be insightful.The company's ROCE of 17.44% is a positive signal. A consistently high ROCE indicates efficient capital allocation and potentially contributes to building an economic moat. This moat, in the form of pricing power or cost advantages, protects the company from competition and allows it to generate sustainable profits. However, it is essential to determine if this ROCE is sustainable and not a result of temporary factors. Detailed analysis of their cost structure, product portfolio and pricing strategies is important to evaluate the sustainability of their current ROCE.
Comparing Coral Laboratories Ltd to its peers like Smruthi Organics Ltd and Balaxi Pharmaceuticals Ltd necessitates analyzing their financial ratios, debt levels, and cash flow generation capabilities. Furthermore, understanding the competitive dynamics within the specific segments Coral Laboratories operates in is critical. A thorough review of their balance sheet and future capital expenditure plans will give further insight into the financial health and long-term sustainability of the business model.
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Coral Laboratories Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of CORALAB across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Excellent ROCE Performance (17.44%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (15.67%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Attractive Valuation (P/E: 9.95 vs Industry: 31.77)
Observation: Trading at discount to industry peers.
Analysis: P/E below industry average may present value opportunity.
Excellent EPS Growth (28.24% CAGR)
Observation: Outstanding 5-year earnings per share compound growth.
Analysis: EPS CAGR >15% indicates strong wealth creation potential.
Strong Profit Growth Track Record (28.24% CAGR)
Observation: Consistent 5-year profit compound annual growth rate.
Analysis: Profit CAGR >15% demonstrates scalable business model.
Debt-Free Balance Sheet (D/E: 0.00)
Observation: Low leverage provides financial flexibility and reduced risk.
Analysis: Conservative debt structure offers resilience during economic downturns.
Strong Interest Coverage (109.00x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Balanced Promoter Holding (71.51%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
2 factors identified
Profit Decline Concern (-12.70%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Revenue Contraction (-40.96%)
Observation: Sales decline may indicate market challenges or competitive pressures.
Analysis: Negative revenue growth requires analysis of market conditions.
Coral Laboratories Ltd Financial Statements
Comprehensive financial data for Coral Laboratories Ltd including income statement, balance sheet and cash flow
About CORALAB (Coral Laboratories Ltd)
Coral Laboratories Ltd is a dynamic pharmaceutical company dedicated to developing, manufacturing, and marketing a broad spectrum of healthcare solutions. With a strong commitment ...to quality and innovation, Coralab focuses on creating accessible and affordable medicines that address diverse medical needs across various therapeutic areas. Their state-of-the-art manufacturing facilities adhere to the highest international standards, ensuring the production of safe, effective, and reliable pharmaceutical products. Coralab continuously invests in research and development to stay at the forefront of pharmaceutical advancements and deliver innovative solutions that improve patient outcomes. Coralab's comprehensive product portfolio encompasses a wide range of therapeutic categories, catering to both acute and chronic conditions. These include formulations for managing infectious diseases, such as antibiotics and antifungals, as well as treatments for gastrointestinal disorders, pain management, and respiratory ailments. The company also offers a diverse selection of medications for cardiovascular health, diabetes management, and parasitic infections. With a focus on patient well-being, Coralab is committed to providing healthcare professionals and patients with a wide array of treatment options to enhance their quality of life. Coralab operates with a global perspective, serving markets in India and beyond. Through strategic partnerships and a robust distribution network, the company strives to make its pharmaceutical products accessible to patients worldwide. With a strong emphasis on ethical business practices and a customer-centric approach, Coralab aims to build lasting relationships with healthcare providers and stakeholders. Driven by a passion for improving global health, Coralab continues to expand its reach and impact, delivering high-quality pharmaceutical solutions to meet the evolving needs of patients around the world.
Company Details
Key Leadership
Corporate Events
CORALAB Share Price: Frequently Asked Questions
What is the current share price of Coral Laboratories Ltd (CORALAB)?
As of 30 Mar 2026, 12:06 pm IST, Coral Laboratories Ltd share price is ₹370.55. The CORALAB stock has a market capitalisation of ₹175.62 (Cr) on NSE/BSE.
Is CORALAB share price Overvalued or Undervalued?
CORALAB share price is currently trading at a P/E ratio of 9.95x, compared to the industry average of 31.77x. Based on this relative valuation, the Coral Laboratories Ltd stock appears to be Undervalued against its sector peers.
What is the 52-week high and low of CORALAB share price?
The 52-week high of CORALAB share price is ₹784.55 and the 52-week low is ₹360.00. These values are updated daily from NSE/BSE price data.
What factors affect the Coral Laboratories Ltd share price?
Key factors influencing CORALAB share price include quarterly earnings growth (Sales Growth: -40.96%), raw material costs, government infrastructure spending, and institutional flows (FII/DII holding).
Is Coral Laboratories Ltd a good stock for long-term investment?
Coral Laboratories Ltd shows a 5-year Profit Growth of 28.24% and an ROE of 13.06%. Long-term investors should consider these fundamentals alongside the debt-to-equity ratio of 0.00 before investing in CORALAB shares.
How does Coral Laboratories Ltd compare with its industry peers?
Coral Laboratories Ltd competes with major peers in the Pharmaceuticals. Investors should compare CORALAB share price P/E of 9.95x and ROE of 13.06% against the industry averages to determine competitive standing.
What is the P/E ratio of CORALAB and what does it mean?
CORALAB share price has a P/E ratio of 9.95x compared to the industry average of 31.77x. Investors pay ₹10 for every ₹1 of annual earnings.
How is CORALAB performing according to Bull Run's analysis?
CORALAB has a Bull Run fundamental score of 55/100, indicating moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters.
What sector and industry does CORALAB belong to?
CORALAB operates in the Pharmaceuticals industry. This classification helps understand the competitive landscape and sector-specific trends affecting Coral Laboratories Ltd share price.
What is Return on Equity (ROE) and why is it important for CORALAB?
CORALAB has an ROE of 13.06%, which shows decent profitability but room for improvement. ROE measures how efficiently Coral Laboratories Ltd generates profits from shareholders capital.
How is CORALAB debt-to-equity ratio and what does it indicate?
CORALAB has a debt-to-equity ratio of 0.00, which indicates conservative financing with low financial risk.
What is CORALAB dividend yield and is it a good dividend stock?
CORALAB offers a dividend yield of 0.30%, meaning you receive ₹0.30 annual dividend for every ₹100 invested in Coral Laboratories Ltd shares.
How has CORALAB share price grown over the past 5 years?
CORALAB has achieved 5-year growth rates of: Sales Growth 10.26%, Profit Growth 28.24%, and EPS Growth 28.24%.
What is the promoter holding in CORALAB and why does it matter?
Promoters hold 71.51% of CORALAB shares, with 0.00% pledged. High promoter holding often indicates strong management confidence in Coral Laboratories Ltd.
What is CORALAB market capitalisation category?
CORALAB has a market capitalisation of ₹176 crores, placing it in the Small-cap category.
How volatile is CORALAB stock?
CORALAB has a beta of N/A. A beta > 1 suggests the Coral Laboratories Ltd stock is more volatile than the market, while a beta < 1 suggests it is less volatile.
What is CORALAB operating profit margin trend?
CORALAB has a 5-year average Operating Profit Margin (OPM) of 15.67%, indicating the company's operational efficiency.
How is CORALAB quarterly performance?
Recent quarterly performance shows Coral Laboratories Ltd YoY Sales Growth of -40.96% and YoY Profit Growth of -12.70%.
What is the institutional holding pattern in CORALAB?
CORALAB has FII holding of 0.00% and DII holding of 0.00%. Significant institutional holding often suggests professional confidence in the Coral Laboratories Ltd stock.